Advertisement

Table of Contents

July 04, 2019; 134 (1)

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS

  • Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes
    Jérôme Hadjadj, Nathalie Aladjidi, Helder Fernandes, Guy Leverger, Aude Magérus-Chatinet, Fabienne Mazerolles, Marie-Claude Stolzenberg, Sidonie Jacques, Capucine Picard, Jérémie Rosain, Cécile Fourrage, Sylvain Hanein, Mohammed Zarhrate, Marlène Pasquet, Wadih Abou Chahla, Vincent Barlogis, Yves Bertrand, Isabelle Pellier, Elodie Colomb Bottollier, Fanny Fouyssac, Pascale Blouin, Caroline Thomas, Nathalie Cheikh, Eric Dore, Corinne Pondarre, Dominique Plantaz, Eric Jeziorski, Frédéric Millot, Nicolas Garcelon, Stéphane Ducassou, Yves Perel, Thierry Leblanc, Bénédicte Neven, Alain Fischer and Frédéric Rieux-Laucat on behalf of members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE)
  • PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
    PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
    Philippe Armand, Yi-Bin Chen, Robert A. Redd, Robin M. Joyce, Jad Bsat, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Parastoo B. Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreofe O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp and Alex F. Herrera

LYMPHOID NEOPLASIA

  • A niche-dependent myeloid transcriptome signature defines dormant myeloma cells
    A niche-dependent myeloid transcriptome signature defines dormant myeloma cells
    Weng Hua Khoo, Guy Ledergor, Assaf Weiner, Daniel L. Roden, Rachael L. Terry, Michelle M. McDonald, Ryan C. Chai, Kim De Veirman, Katie L. Owen, Khatora S. Opperman, Kate Vandyke, Justine R. Clark, Anja Seckinger, Natasa Kovacic, Akira Nguyen, Sindhu T. Mohanty, Jessica A. Pettitt, Ya Xiao, Alexander P. Corr, Christine Seeliger, Mark Novotny, Roger S. Lasken, Tuan V. Nguyen, Babatunde O. Oyajobi, Dana Aftab, Alexander Swarbrick, Belinda Parker, Duncan R. Hewett, Dirk Hose, Karin Vanderkerken, Andrew C. W. Zannettino, Ido Amit, Tri Giang Phan and Peter I. Croucher
  • Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8<sup>+</sup> T cells and impede CAR T-cell efficacy
    Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
    Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark-David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater and Gerritje J. W. van der Windt

MYELOID NEOPLASIA

  • RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
    RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
    Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Yimin Qian, Kanak Raina, Kimal Rajapakshe, Dimuthu Perera, Cristian Coarfa, Tapan M. Kadia, Joseph D. Khoury, Dyana T. Saenz, David N. Saenz, Anuradha Illendula, Koichi Takahashi, Steven M. Kornblau, Michael R. Green, Andrew P. Futreal, John H. Bushweller, Craig M. Crews and Kapil N. Bhalla

TRANSFUSION MEDICINE

LETTERS TO BLOOD

BLOOD WORK